Literature DB >> 8102826

Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis.

M Furione1, S Guillot, D Otelea, J Balanant, A Candrea, R Crainic.   

Abstract

To determine how oral poliovirus vaccine (Sabin) strains evolve during replication in humans and to confirm the etiology of vaccine-associated paralytic poliomyelitis (VAPP), we examined 70 vaccine-derived strains isolated from VAPP cases. Two distant sequences of the poliovirus genome were targeted for a double restriction fragment length polymorphism assay (RFLP) of reverse-transcribed genomic segments amplified by PCR, an extension of the method that we described previously (Balanant et al., 1991). One (RFLP-1) was a 480-long nucleotide sequence coding for the N-terminal part of the VP1 capsid polypeptide, situated in the 5' third of the viral genome (nucleotides 2401-2880). The other (RFLP-3D1) was a 291-long nucleotide sequence coding for a part of the viral polymerase, situated near the 3' end of the genome (nucleotides 6086-6376). Strain-specific restriction profiles could be generated for different field isolates by using three restriction enzymes in each case: HaeIII, DdeI, and HpaII for RFLP-1 and HaeIII, DdeI and RsaI for RFLP-3D1. With few exceptions, the vaccine-specific RFLP profiles were found to be conserved in both regions during replication of these viruses in humans. Thus, RFLP could be used as a marker so as to identify the origin of viral isolates at both ends of their genome. Whether viral isolates were vaccine-derived was determined by using strain-specific monoclonal antibodies and RFLP-1. Among the 70 isolates, 21 of the 43 type 2 strains and 15 of the 22 type 3 strains had a recombinant genome. None of the 5 type 1 Sabin-derived isolates was found to be recombinant. Both intertypic vaccine/vaccine and vaccine/non-vaccine recombinants were detected. Partial nucleotide sequencing confirmed the RFLP results in all cases that were investigated. In one case, it was possible to predict the recombination junction site from the restriction profiles. This site was more precisely localized by sequencing. The C6203 > U nucleotide substitution, which is suspected to contribute to the reversion toward neurovirulence of the attenuated Sabin 1 strain, was detected in almost all the recombinant genomes containing Sabin 1-specific sequences at the 3' extremity. This mutation was detected by identification of the modified RsaI profile in the RFLP-3D1. The results presented in this paper suggest that recombination, alone or together with mutation, might be one of the mechanisms of the reversion toward neurovirulence of attenuated vaccine strains and of the natural evolution of poliovirus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102826     DOI: 10.1006/viro.1993.1468

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  58 in total

1.  Assessment of poliovirus eradication in Japan: genomic analysis of polioviruses isolated from river water and sewage in toyama prefecture.

Authors:  K Matsuura; M Ishikura; H Yoshida; T Nakayama; S Hasegawa; S Ando; H Horie; T Miyamura; T Kitamura
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

2.  Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Authors:  G V Gavrilin; E A Cherkasova; G Y Lipskaya; O M Kew; V I Agol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Investigation of the presence of recombinant polioviruses in the hit population in Albania during the 1996 outbreak.

Authors:  Jill Marturano; Lucia Fiore
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

4.  RNA recombination plays a major role in genomic change during circulation of coxsackie B viruses.

Authors:  M Steven Oberste; Silvia Peñaranda; Mark A Pallansch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

6.  Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001.

Authors:  Hiroyuki Shimizu; Bruce Thorley; Fem Julia Paladin; Kerri Anne Brussen; Vicki Stambos; Lilly Yuen; Andi Utama; Yoshio Tano; Minetaro Arita; Hiromu Yoshida; Tetsuo Yoneyama; Agnes Benegas; Sigrun Roesel; Mark Pallansch; Olen Kew; Tatsuo Miyamura
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

7.  Recombination in circulating enteroviruses.

Authors:  Alexander N Lukashev; Vasilii A Lashkevich; Olga E Ivanova; Galina A Koroleva; Ari E Hinkkanen; Jorma Ilonen
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China.

Authors:  Hong-Mei Liu; Du-Ping Zheng; Li-Bi Zhang; M Steven Oberste; Olen M Kew; Mark A Pallansch
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Identification of vaccine-related polioviruses by hybridization with specific RNA probes.

Authors:  L De; B Nottay; C F Yang; B P Holloway; M Pallansch; O Kew
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.